Alzheimer’s disease market set to double to $10.4 Billion by 2021
pharmafile | February 11, 2016 | News story | Research and Development, Sales and Marketing | Alzheimer's disease
The Alzheimer’s disease market will more than double from just under $5 billion in 2014 to an estimated $10.4 billion in 2021, at a Compound Annual Growth Rate (CAGR) of 11%, according to business intelligence provider GBI Research.
The company’s latest report says this growth will occur across the eight major markets of the US, Canada, France, Germany, Italy, Spain, the UK, and Japan, and will be driven largely by the increased prevalence of the disease during the forecast period, but also innovation in treatments.
Yasser Mushtaq, senior analyst for GBI Research, noted the fact that incidence rates increase rapidly after the age of 65, and that an ageing global population will escalate the growth of the Alzheimer’s problem.
Mushtaq comments: “The fact that people are living longer across the globe means more cases of the disease are developing, and this has posed a growing public health crisis, which represents a very serious disease burden for patients and carers alike.
“Despite the urgent need to develop more effective treatments for Alzheimer’s disease, thorough research is being carried out into understanding the disease, as its underlying pathology remains unknown.
“However, these extensive studies have helped to develop the research and development process within this indication, providing hope for the future of Alzheimer’s disease therapeutics.”
Although disease prevalence will be the strongest driver of market growth, GBI also anticipates some of the increase to come from innovation in the treatment pipeline. Alzheimer’s drug candidates fail at a much higher rate during development than the industry average, and attrition rates across all phases is around 05%, but an increased understanding of the disease’s mechanisms and the reasons for the treatment’s failures should lead to more successful drugs in the coming years.
The report is published in the same week Heptares announced positive early-stage trial results for a new drug to treat cognitive impairment due to dementia and schizophrenia.
Mushtaq adds: “While many of the later-stage therapies focus on common targets, the earlier stages of the pipeline do not appear to follow this trend, as they contain many first-in-class molecules with novel molecular targets within the context of Alzheimer’s disease therapeutics.
“The primary new approvals for drugs that will drive growth during the forecast period will supplement current market leaders and offer greater therapeutic options. Promising examples include verubecestat, aducanumab and azeliragon, all of which have demonstrated clinical benefit and will be approved during the forecast period.”
Joel Levy
Related Content
Sanofi completes acquisition of Vigil Neuroscience to early neurology pipeline
Sanofi has announced that it has finalised its acquisition of Vigil Neuroscience, a US-based biotechnology …
Roche receives CE Mark for blood test to help rule out Alzheimer’s
Roche has been granted CE Mark approval for its Elecsys pTau181 test, the first in …
Sanofi to acquire Vigil Neuroscience, adding Alzheimer’s disease candidate to early-stage pipeline
Sanofi has announced an agreement to acquire Vigil Neuroscience, a biotech company focused on therapies …
